These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 12682267)
1. A peptide derived from the parasite receptor, complement C2 receptor inhibitor trispanning, suppresses immune complex-mediated inflammation in mice. Inal JM; Schneider B; Armanini M; Schifferli JA J Immunol; 2003 Apr; 170(8):4310-7. PubMed ID: 12682267 [TBL] [Abstract][Full Text] [Related]
2. Complement C2 receptor inhibitor trispanning and the beta-chain of C4 share a binding site for complement C2. Inal JM; Schifferli JA J Immunol; 2002 May; 168(10):5213-21. PubMed ID: 11994478 [TBL] [Abstract][Full Text] [Related]
3. CRIT peptide interacts with factor B and interferes with alternative pathway activation. Hui KM; Magnadóttir B; Schifferli JA; Inal JM Biochem Biophys Res Commun; 2006 May; 344(1):308-14. PubMed ID: 16600177 [TBL] [Abstract][Full Text] [Related]
4. A Schistosoma protein, Sh-TOR, is a novel inhibitor of complement which binds human C2. Inal JM; Sim RB FEBS Lett; 2000 Mar; 470(2):131-4. PubMed ID: 10734221 [TBL] [Abstract][Full Text] [Related]
5. A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats. Strachan AJ; Woodruff TM; Haaima G; Fairlie DP; Taylor SM J Immunol; 2000 Jun; 164(12):6560-5. PubMed ID: 10843715 [TBL] [Abstract][Full Text] [Related]
6. Complement C2 receptor inhibitor trispanning: a novel human complement inhibitory receptor. Inal JM; Hui KM; Miot S; Lange S; Ramirez MI; Schneider B; Krueger G; Schifferli JA J Immunol; 2005 Jan; 174(1):356-66. PubMed ID: 15611259 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of complement activation by recombinant Sh-CRIT-ed1 analogues. Oh KS; Kweon MH; Rhee KH; Ho Lee K; Sung HC Immunology; 2003 Sep; 110(1):73-9. PubMed ID: 12941143 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist. Strachan AJ; Shiels IA; Reid RC; Fairlie DP; Taylor SM Br J Pharmacol; 2001 Dec; 134(8):1778-86. PubMed ID: 11739255 [TBL] [Abstract][Full Text] [Related]
9. Expression of functional recombinant von Willebrand factor-A domain from human complement C2: a potential binding site for C4 and CRIT. Hui KM; Orriss GL; Schirmer T; Magnadóttir B; Schifferli JA; Inal JM Biochem J; 2005 Aug; 389(Pt 3):863-8. PubMed ID: 15823096 [TBL] [Abstract][Full Text] [Related]
10. Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in rats. Yeh CG; Marsh HC; Carson GR; Berman L; Concino MF; Scesney SM; Kuestner RE; Skibbens R; Donahue KA; Ip SH J Immunol; 1991 Jan; 146(1):250-6. PubMed ID: 1824590 [TBL] [Abstract][Full Text] [Related]
11. Distinct tissue site-specific requirements of mast cells and complement components C3/C5a receptor in IgG immune complex-induced injury of skin and lung. Baumann U; Chouchakova N; Gewecke B; Köhl J; Carroll MC; Schmidt RE; Gessner JE J Immunol; 2001 Jul; 167(2):1022-7. PubMed ID: 11441111 [TBL] [Abstract][Full Text] [Related]
12. Complement C2 receptor inhibitor trispanning: from man to schistosome. Inal JM Springer Semin Immunopathol; 2005 Nov; 27(3):320-31. PubMed ID: 16235057 [TBL] [Abstract][Full Text] [Related]
13. Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo. Moran P; Beasley H; Gorrell A; Martin E; Gribling P; Fuchs H; Gillett N; Burton LE; Caras IW J Immunol; 1992 Sep; 149(5):1736-43. PubMed ID: 1380537 [TBL] [Abstract][Full Text] [Related]